| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
CalciMedica, Inc.$0.93
-0.04 (-4.23%)
D 24Pipeline Score Overvalued Biotech · Clinical
Market Cap
9.94 M
EPS
-1.30
P/E Ratio
-
Value Trade
93.40 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.48 M
Operating CF
-4.86 M
Total Assets
8.61 M
Total Liabilities
9.71 M
Equity
-1.10 M
D/E Ratio
12,345
-7.93 %
Week
2.09 %
1 Month
14.28 %
3 Month
-80.16 %
6 Month
-88.07 %
5 Year
-88.07 %
All Time
Cash Data
Cash Position
8.16 M
Monthly Burn
1.62 M
Runway
3.3 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
190.13 K
52 Week Range
0.46 - 7.20
% held by Insiders
53.61 %
% held by Institutions
6.68 %
Enterprise Value
8.47 M
Total Shares
14.39 M
Short %
28.84 %
Float Shares
5.73 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CalciMedica, Inc.
236Total events
6Upcoming
39Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 6
Event history 230
Q3 2026
◆Timing GuidanceAuxoraPresentation
Expected FDA feedback on pivotal program design for Auxora in acute pancreatitis
acute pancreatitissource ↗
Jun 24, 2026
▲FDA Feedback ReceivedAuxoraFDA Meeting
FDA reviewed protocol amendment and interim safety data for KOURAGE trial; no comments received
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
Jun 24, 2026
Q2 2026
◆FDA Feedback ReceivedAuxoraFDA Meeting
FDA feedback regarding potential future development of Auxora in AKI expected in 2Q 2026
acute kidney injury with acute hypoxemic respiratory failuresource ↗
Apr 2026
▲Preclinical PoCAuxoraPreclinical
Preclinical data published in Human Immunology in April 2026
inflammatory and immune-mediated diseasessource ↗
Mar 3, 2026
▲Safety Data UpdateAuxoraClinical Data
Internal and external safety review of KOURAGE data found no drug-related toxicity
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
Mar 3, 2026
▲FDA Feedback ReceivedAuxoraFDA Meeting
Constructive FDA engagement for pivotal program in AP
acute pancreatitis (AP)source ↗
Mar 3, 2026
▲PublicationCM5480Presentation
JCI Insight publication of preclinical data for CM5480 in PAH
pulmonary arterial hypertension (PAH)source ↗
Mar 3, 2026
Drug Pipeline Intelligence
D24
Pipeline Score $3M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.3x
rNPV / MCap Top 24%
Micro Cap (rank 693 of 911)
Percentile RankCalciMedica, Inc. faces pipeline headwinds (24/100), with $527M risk-adjusted pipeline value, led by Auxora in Pneumonia (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Auxora Small molecule | Pneumonia | Phase 2 | NCT04345614 | 21% | $154M | COMPLETED | 314 | - | - | Jul 30, 2021 | - | Mar 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Auxora | acute pancreatitis | Phase 2b | 2025-09-02 | positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed Read More | CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Read More | |
Auxora | acute pancreatitis | Phase 2b | 2025-09-02 | positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed Read More | CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Read More | |
Auxora | acute pancreatitis | Phase 2b | 2025-09-02 | positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed Read More | CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CALC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CALC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CALC▼ -25.6%on this news
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica has announced a private placement financing of up to $49 million to support its pulmonary hypertension program. The funds will be used for a Phase 1b proof-of-concept study of Auxora in patients with pulmonary arterial hypertension, with data expected by mid-2027. Additionally, the financing will aid in advancing CM5480 towards IND clearance, also anticipated by mid-2027.
Read more →CALC▼ -25.6%on this newsshared move
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica has received FDA confirmation to proceed with the clinical development of Auxora in the Phase 2 KOURAGE trial for acute kidney injury. The FDA reviewed a protocol amendment and interim safety data, resulting in no comments or questions, allowing patient dosing to continue. The company had previously paused enrollment due to safety concerns but found no drug-related toxicity.
Read more →CALC▲ +6.6%on this news· ran to +17% by day 1
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates FDA feedback on the Auxora pivotal program in acute pancreatitis and potential future development in acute kidney injury
CalciMedica reported its first-quarter financial results for 2026, highlighting key updates on its clinical programs. The company is in active discussions with the FDA regarding its Auxora program for acute pancreatitis and expects feedback in the second quarter of 2026. Positive Phase 2b trial results were published, indicating Auxora's efficacy in treating patients with acute pancreatitis. Additionally, preclinical studies for CalciMedica's CM5480 candidate in pulmonary hypertension are underway, with an IND submission anticipated in 2027.
Read more →CALC▲ +14.4%on this news· ran to +43% by day 3
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica reported its 2025 financial results, highlighting no drug-related toxicity in the Phase 2 KOURAGE trial for acute kidney injury. The company anticipates finalizing the pivotal program design for acute pancreatitis in the first half of 2026 and advancing its second CRAC channel inhibitor, CM5480, for pulmonary arterial hypertension. Despite a net loss of $29.6 million, CalciMedica's cash position is expected to sustain operations into late 2026.
Read more →CALC▼ -75.6%on this news· ran to -87% by day 3
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
CalciMedica has announced the discontinuation of its Phase 2 KOURAGE trial for Auxora in patients with acute kidney injury, following a recommendation from the Independent Data Monitoring Committee due to safety concerns. The company plans to reevaluate the trial design and patient enrollment criteria based on a comprehensive review of the unblinded clinical data. Despite this setback, CalciMedica remains optimistic about Auxora's potential in treating acute inflammatory conditions.
Read more →CALCCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica has reported its financial results for Q3 2025, highlighting ongoing enrollment in the Phase 2 KOURAGE trial for Auxora in acute kidney injury. The company is optimistic following positive discussions with the FDA regarding a pivotal trial in acute pancreatitis. Their cash position is projected to support operations into the second half of 2026, despite an increase in net loss compared to the previous year.
Read more →CALCCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
CalciMedica announced promising preclinical data for CM5480, a CRAC channel inhibitor, as a potential therapy for pulmonary arterial hypertension (PAH). The study demonstrated that CM5480, both as a monotherapy and in combination with existing treatments, significantly improved cardiac function and reduced pulmonary hypertension in animal models. These findings support further exploration of CM5480 in clinical settings.
Read more →CALCCalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
CalciMedica presented promising preclinical data on Auxora at ASN Kidney Week 2025, showing its effectiveness in reducing IL-17-related inflammation and improving kidney function in a rat model of acute kidney injury (AKI). The findings support the ongoing Phase 2 KOURAGE trial evaluating Auxora for severe AKI with respiratory failure. The study highlights Auxora's potential as a transformative therapy for critically ill patients.
Read more →CALCCalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
CalciMedica has partnered with Telperian to integrate AI tools for analyzing clinical trial data of Auxora, its lead compound. This collaboration aims to enhance the understanding of treatment effects across patient subgroups and refine pivotal trial designs. The partnership is expected to expedite insights into the drug's efficacy for acute inflammatory and immunologic conditions.
Read more →CALC▲ +14.8%on this news
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Rachel Leheny will discuss the company's innovative therapies targeting CRAC channels for inflammatory and immunologic diseases. CalciMedica's lead product, Auxora, has shown positive results in clinical trials and is being evaluated in multiple ongoing studies.
Read more →CALC▼ -10.1%on this news
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expect
CalciMedica announced its financial results for the second quarter of 2025, highlighting ongoing enrollment in the Phase 2 KOURAGE trial for Auxora targeting acute kidney injury (AKI) with respiratory failure, with data expected in early 2026. The company reported productive discussions with the FDA regarding a pivotal trial for Auxora in acute pancreatitis, anticipated by the end of 2025. Despite these developments, CalciMedica reported an increased net loss and a decline in other income, although its cash position remains strong to support operations into mid-2026.
Read more →CALCCalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
CalciMedica Inc. will participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025. CEO Rachel Leheny will engage in a fireside chat, which will be accessible via a live webcast. The company focuses on CRAC channel inhibition therapies for inflammatory and immunologic diseases, with promising clinical results from its lead product candidate, Auxora.
Read more →CALCCalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
CalciMedica has published a manuscript in the American Journal of Nephrology detailing the design and rationale of its Phase 2 KOURAGE trial for Auxora in treating acute kidney injury (AKI) with respiratory failure. The study aims to enroll around 150 patients and assess the efficacy of Auxora, which has shown positive results in preclinical models and previous trials. The trial's primary endpoint focuses on days alive without the need for a ventilator or dialysis.
Read more →CALCCalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
CalciMedica Inc. announced its participation in the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting, where it will present a symposium on 'Auxora for the Treatment of AKI'. The event will feature several presentations by leading experts discussing CRAC channels and their role in AKI. Webcasts of the presentations will be available on CalciMedica's investor relations website.
Read more →CALC▼ -5.9%on this news
Mastering Slot Game Performance: The Critical Role of Load Times
The article discusses the critical importance of load times in slot games within the digital gambling industry. It highlights how performance factors, particularly loading speed, directly affect player retention and satisfaction. Various optimization techniques are explored, emphasizing the need for developers to prioritize load time improvements to enhance user experience and platform reputation.
Read more →CALCCalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected
CalciMedica has reported its financial results for the first quarter of 2025, revealing a net loss of $5.9 million amidst ongoing clinical trials. Notably, the company is continuing enrollment in the Phase 2 KOURAGE trial for its lead product, Auxora, with data results anticipated by the end of 2025. A post-hoc analysis demonstrated a significant reduction in mortality among patients treated with Auxora for acute kidney injury. The company's cash position is projected to sufficiently support operations into mid-2026, despite the recent financial losses.
Read more →CALCCalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Inc. announced its upcoming presentations at two significant medical meetings: Digestive Disease Week 2025 and the American Society of Nephrology conference. The company's Chief Medical Officer, Sudarshan Hebbar, will participate in an oral presentation and a panel discussion, while a poster presentation will also feature important findings related to acute pancreatitis. CalciMedica's focus on CRAC channel inhibition aims to address significant health challenges in inflammatory and immunologic diseases. The involvement in these events signals the company's ongoing commitment to advancing its research and development efforts.
Read more →CALCCalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
CalciMedica Inc. has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference, where CEO Rachel Leheny will present. The company, focused on novel CRAC channel inhibition therapies for inflammatory illnesses, aims to increase visibility and engagement within the biopharmaceutical sector. CalciMedica's lead product candidate, Auxora™, has shown positive results in clinical trials, yet challenges remain as various trials are still in progress without any approved therapies for the targeted conditions.
Read more →CALCCalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the en
CalciMedica reported its 2024 financial results alongside updates on its clinical trials, including the ongoing Phase 2 KOURAGE trial for Auxora in acute kidney injury and respiratory failure. Notably, a post-hoc analysis indicated a 62.7% relative reduction in mortality for patients treated with Auxora in a prior COVID-19 pneumonia study. The company has a robust cash position expected to sustain operations through mid-2026, but announced a net loss of $13.7 million for 2024. Future milestones include a planned end-of-Phase 2 meeting with the FDA for acute pancreatitis treatment.
Read more →CALC▼ -6.2%on this news
CalciMedica Secures Credit Facility for Up to $32.5 Million $10 million funded at close extends cash runway into mid-2026
CalciMedica has secured a credit facility of up to $32.5 million, including an initial $10 million funding that extends its cash runway into mid-2026. The funds will support the development of its product pipeline, particularly as it prepares for several critical clinical milestones in 2025. The facility allows for additional funding contingent on achieving specific milestones, providing substantial financial flexibility for the company's ongoing and upcoming trials. CEO Rachel Leheny highlighted the importance of this funding in enabling the company to reach its objectives in treating acute inflammatory and immunologic diseases.
Read more →CALCCalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora in Severe COVID-19 Pneumonia at the 30 th International AKI & CRRT Conference 62.7% relative reduction in mortality at day 30,
CalciMedica presented promising data from a post-hoc analysis of the Phase 2 CARDEA trial of Auxora, indicating a 62.7% relative reduction in mortality at day 30 for patients with acute kidney injury (AKI) treated with the drug. This significant reduction was maintained through day 60 and surpassed the overall study population's 56.3% reduction in mortality. The company continues to conduct an ongoing Phase 2 trial, KOURAGE, expected to yield results in 2025. The findings underscore the potential of CRAC channel inhibition in treating inflammatory and immunologic diseases associated with AKI.
Read more →CALCCalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
CalciMedica Inc. announced a plenary presentation at the 30th International AKI & CRRT Conference scheduled for March 3-6, 2025, in San Diego. The presentation will be led by Chief Medical Officer Sudarshan Hebbar, M.D., and will discuss the role of ORAI-1 in acute kidney injury. The company is renowned for its CRAC channel inhibition therapies aimed at inflammatory and immunologic conditions and has shown positive clinical results in its ongoing trials.
Read more →CALCCalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CalciMedica Inc. announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference scheduled for February 12, 2025. CEO Rachel Leheny will present, discussing the company's innovative CRAC channel inhibition therapies that target acute and chronic inflammatory and immunologic diseases. The company has reported positive results from clinical trials of its lead product candidate, Auxora™, including studies related to acute pancreatitis and COVID pneumonia. Currently, CalciMedica is advancing trials for acute kidney disease and pediatric patients with asparaginase-induced pancreatic toxicity.
Read more →CALCCalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
CalciMedica Inc. has appointed Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025. Dr. Glicklich brings over 20 years of biopharmaceutical experience, including leadership roles in clinical development. His expertise is expected to enhance the company's abilities as it progresses towards pivotal trials for its drug Auxora, aimed at addressing acute pancreatitis and acute kidney injury. CalciMedica is focused on developing therapies for serious inflammatory and immunologic conditions with significant unmet medical needs.
Read more →CALCCalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
CalciMedica Inc. announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for December 4, 2024. CEO Rachel Leheny will present at the event, which highlights the company's focus on developing therapies for inflammatory and immunologic diseases. CalciMedica's lead candidate, Auxora™, has shown promising results in multiple clinical trials, addressing critical health issues without existing approved therapies. The company's ongoing trials further emphasize its commitment to advancing its novel treatment approaches.
Read more →CALCCalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora in acute pancreat
CalciMedica has released its third quarter 2024 financial results alongside updates on its clinical trials. Notably, the company announced positive findings from the CARPO Phase 2b trial of Auxora for acute pancreatitis, including significant reductions in severe respiratory failure. CalciMedica plans to initiate a Phase 3 trial in 2025 and is actively enrolling patients in two other Phase 2 trials addressing acute kidney injury and asparaginase-induced pancreatic toxicity. The company's financial outlook appears stable, with funds expected to support operations through mid-2026.
Read more →CALCCalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
CalciMedica, a clinical-stage biopharmaceutical company, announced the appointment of Stephen Bardin as Chief Financial Officer, succeeding Daniel Geffken. Bardin, who previously served as CFO at atai Life Sciences, is expected to contribute significantly to CalciMedica’s financial strategies and clinical development initiatives. His recent work was pivotal in a successful public financing round. The company is advancing its clinical pipeline, particularly in therapies for acute pancreatitis and acute kidney injury, with promising trial data reported recently.
Read more →CALC▲ +22.1%on this news
CalciMedica Announces Pricing of Public Offering of Common Stock
CalciMedica Inc. has priced an underwritten public offering of 2,720,000 shares of common stock at $3.75 per share, aiming to raise approximately $10.2 million. The offering, to be finalized by November 1, 2024, includes a 30-day option for underwriters to purchase additional shares. The funds raised are expected to support the company's development of novel therapies targeting inflammatory and immunologic diseases, particularly its lead candidate, Auxora, which has shown positive results in clinical trials. However, the company faces risks related to the completion of the offering and meeting customary closing conditions.
Read more →CALC▲ +22.1%on this news
CalciMedica Announces Proposed Public Offering of Common Stock
CalciMedica has announced a proposed public offering of common stock as part of its ongoing efforts to fund its clinical-stage biopharmaceutical initiatives. The company specializes in CRAC channel inhibition therapies targeting acute and chronic inflammatory and immunologic conditions. CalciMedica's lead product, Auxora, has shown promise in previous trials, though the success of the current offering and ongoing clinical trials carries inherent risks. The terms and completion of the offering rest on market conditions and regulatory factors, highlighting the volatility characteristic of public offerings.
Read more →CALC▲ +22.1%on this news
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific
CalciMedica announced positive data from the Phase 2b CARPO trial of Auxora for acute pancreatitis, highlighting a 100% reduction in new-onset severe respiratory failure among patients using the high dose of the drug. The trial demonstrated a significant stratified win ratio and improvements in other key clinical endpoints. As a result, CalciMedica is optimistic about the future development of Auxora, with plans to discuss the Phase 3 trial design with the FDA. This data underlines the drug's potential as a vital treatment in a disease with no approved therapies.
Read more →CALCCalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica Inc. will host a conference call on October 30, 2024, to review the full data set and win ratio analysis from its Phase 2b CARPO trial of Auxora™ in patients with acute pancreatitis. The trial's findings will be presented by Prof. Robert Sutton during the ACG 2024 Annual Scientific Meeting. CalciMedica focuses on developing therapies that inhibit calcium release-activated calcium channels to address severe inflammatory and immunologic conditions.
Read more →CALCCalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
CalciMedica Inc. has announced the acceptance of a late-breaking abstract for a plenary presentation at the ACG 2024 Annual Scientific Meeting. The presentation, led by Prof. Robert Sutton, will focus on the findings from their CARPO clinical trial related to acute pancreatitis with systemic inflammatory response syndrome. With ongoing trials for its lead product candidate Auxora, CalciMedica continues to explore treatment options for inflammatory and immunologic diseases. The meeting will take place from October 28 to 30, 2024, in Philadelphia.
Read more →CALC▲ +7.7%on this news· ran to +27% by day 3
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CalciMedica Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. CEO Rachel Leheny, Ph.D., will present the company's focus on novel therapies targeting CRAC channels for inflammatory and immunologic diseases. The company has demonstrated positive results with its lead product candidate Auxora™ in clinical trials, indicating potential therapeutic benefits. A live webcast of the presentation will be available for viewing.
Read more →CALCCalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Positive topline data announced from CARPO, Phase 2b trial of Auxora in acute pancreatitis (AP); additional data to be p
CalciMedica has reported positive topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis, meeting its primary objectives and setting the stage for future FDA discussions and a potential Phase 3 trial. The first patient has been enrolled in the KOURAGE trial for severe acute kidney injury, with topline data expected in 2025. Despite these advancements, the company reported financial losses of approximately $6.5 million for the quarter, and its future success relies on continued favorable outcomes from its clinical trials.
Read more →CALCCalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
CalciMedica has commenced dosing the first patient in its Phase 2 KOURAGE trial, focusing on Auxora for treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This trial aims to assess the efficacy of Auxora in patients with Stage 2 and 3 AKI, following encouraging preclinical results. Data from the trial is expected to be available in 2025, underlining the urgency of addressing the serious and often fatal nature of AKI, which currently lacks approved therapies.
Read more →CALCCalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
CalciMedica Inc. announced that its CEO, Rachel Leheny, will present at two healthcare investment conferences on July 15, 2024. These presentations are part of the company's efforts to raise awareness about its novel calcium release-activated calcium (CRAC) channel inhibition therapies aimed at treating severe inflammatory and immunologic diseases. CalciMedica continues to demonstrate progress with its lead product candidate, Auxora™, which has shown favorable results in clinical trials, as well as ongoing studies expected to yield data in 2025.
Read more →CALC▲ +7.3%on this news
CalciMedica Set to Join Russell Microcap® Index
CalciMedica Inc. has announced its upcoming inclusion in the Russell Microcap® Index, effective July 1, 2024. This recognition follows the company's growth trajectory since going public in early 2023. The Russell Indexes are important benchmarks used by investment managers and institutional investors, which will enhance CalciMedica’s visibility in the market. The company is engaged in developing innovative therapies aimed at crucial gaps in treatment for inflammatory and immunologic illnesses.
Read more →CALC▼ -32.4%on this newsshared move
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reducti
CalciMedica has announced positive topline data from its Phase 2b CARPO trial of Auxora for acute pancreatitis. The trial achieved its primary objective, showing a significant reduction in median time to solid food tolerance and severe organ failure among patients. The results indicate Auxora's potential benefits for critically ill patients with acute inflammatory diseases, prompting plans for a Phase 3 trial. The trial met its enrollment target of 216 participants and reaffirmed Auxora's safety profile.
Read more →CALC▼ -10%on this news· ran to -39% by day 1shared move
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica Inc. has announced a conference call scheduled for June 27, 2024, to discuss topline data from its Phase 2b CARPO trial of Auxora™ in acute pancreatitis. The company is focused on developing therapies targeting calcium release-activated calcium channels for inflammatory diseases. Auxora™ has previously demonstrated positive clinical results in earlier trials. CalciMedica is actively engaged in multiple ongoing clinical studies, indicating a robust pipeline in their therapeutic development.
Read more →CALC▼ -7.1%on this news
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Last patient enrolled in CARPO, Phase 2b trial of Auxora in acute pancreatitis (AP); topline data expected in 2Q 2024 KOU
CalciMedica has reported its financial results for Q1 2024, highlighting important clinical updates and milestones. The company completed patient enrollment in its Phase 2b CARPO trial for Auxora in acute pancreatitis and expects topline data by 2Q 2024. Additionally, preparations for the Phase 2 KOURAGE trial in severe acute kidney injury are on track, with patient enrollment anticipated soon. Despite the positive progress, the financial report reveals notable operational losses, emphasizing the inherent risks associated with clinical trials.
Read more →CALCCalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
CalciMedica Inc. announced an abstract acceptance for a poster presentation at Digestive Disease Week 2024, showcasing human proteomics data on its lead candidate Auxora. This presentation will highlight Auxora's potential benefits for severe acute pancreatitis, paralleling its effects in COVID-19 pneumonia. The company continues to pursue multiple clinical trials to support the efficacy of Auxora in various inflammatory and immunologic diseases. Topline data from ongoing trials are anticipated in the near future, reflecting the company's commitment to developing innovative therapies.
Read more →CALC▲ +19.6%on this news
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
CalciMedica announced the successful enrollment of the last patient in its Phase 2b CARPO trial for Auxora in the treatment of acute pancreatitis. The trial aimed to assess Auxora's efficacy and dose-response in patients experiencing acute inflammatory conditions. With a target enrollment of 216 patients completed, the company plans to release topline data in the second quarter of 2024. Auxora is significant as there are currently no approved therapies for acute pancreatitis, and the results may offer new hope for the treatment of this serious condition.
Read more →CALCCalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates Enrollment in CARPO, Phase 2b trial of Auxora in acute pancreatitis (AP), on track with topline data expected in 2Q 2024 Auxora granted
CalciMedica reported its 2023 financial results and provided updates on its clinical trials, including progress in the CARPO Phase 2b trial of Auxora for acute pancreatitis with topline data expected in Q2 2024. The company also received FDA clearance for its Phase 2 trial of Auxora in severe acute kidney injury, set to begin in Q2 2024. Additionally, the initial cohort results of another trial presented at ASH 2023 showed promising outcomes for patients treated with Auxora. Financially, CalciMedica's recent private placement is expected to fund operations into the latter half of 2025.
Read more →CALCCalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
CalciMedica presented preclinical data showing that Auxora can hasten kidney function recovery and improve survival rates in a rat model of acute kidney injury (AKI) at the AKI & CRRT Conference. These findings align with previous clinical observations and bolster the rationale for the forthcoming KOURAGE trial, set to enroll patients in Q2 2024. The studies demonstrated a significant improvement in glomerular filtration rate (GFR) and survival in rats treated with Auxora compared to placebo. Overall, the results indicate that Auxora might offer a new therapeutic option for patients suffering from severe AKI.
Read more →CALCCalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
CalciMedica Inc. announced that preclinical data from its study of Auxora for acute kidney injury will be presented at the 29th International AKI & CRRT Conference in San Diego. The data demonstrated that treatment with Auxora improved kidney function, specifically glomerular filtration rate, in a rat model of AKI. The company is developing Auxora as a selective CRAC channel inhibitor and has ongoing clinical trials evaluating its efficacy in various acute inflammatory and immunologic conditions. This preclinical study's findings raise optimism for Auxora's potential therapeutic benefits in a condition currently lacking approved therapies.
Read more →CALC▼ -8.2%on this news· ran to -21% by day 3
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
CalciMedica has received FDA clearance for its IND application to begin a Phase 2 trial of Auxora in patients with severe acute kidney injury (AKI) and associated acute hypoxemic respiratory failure. The study, named KOURAGE, is set to commence in the first half of 2024. The trial aims to address the significant unmet medical need for effective therapies in this patient population, who face high mortality risks. Auxora's previous clinical results have shown promise in treating kidney conditions, which adds to the optimism surrounding this trial.
Read more →CALC▼ -8.2%on this news· ran to -21% by day 3
Developing Novel Therapies for Acute Inflammatory and Immunologic Diseases February 2024 1 Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statement
CalciMedica is actively advancing its clinical trials for Auxora, a therapy targeting acute inflammatory and immunologic diseases. With ongoing studies, positive preliminary results have been observed, particularly for acute pancreatitis, indicating a potential reduction in hospital stay for patients. The company is also pursuing additional indications, with various anticipated milestones in the near future.
Read more →CALC▲ +6.9%on this news
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CalciMedica Inc. is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The company's CEO, Dr. Rachel Leheny, will lead the presentation. CalciMedica focuses on developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases, with their lead product Auxora™ showing promising clinical results. The company is currently conducting a Phase 2b trial for acute pancreatitis and plans additional studies for other conditions in the near future.
Read more →CALCoffice16 activator ✓ Activate Microsoft Office 2016 Full Version Now
The article discusses the office16 activator, a tool designed to activate Microsoft Office 2016, enabling users to access all features without restrictions. It outlines various activation methods, including online and offline options, and emphasizes the importance of using genuine software. The activator simplifies the process, making it accessible for both beginners and advanced users while highlighting potential risks associated with unauthorized tools.
Read more →CALC▲ +7.1%on this news· ran to +17% by day 1shared move
CalciMedica Announces Private Placement of up to Approximately $55 Million $20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approx
CalciMedica has announced a private placement aimed at raising up to approximately $55 million, of which $20.4 million will be received upfront. The funding will facilitate the expansion of the Auxora clinical development to include a Phase 2 trial for acute kidney injury (AKI) anticipated to start in the first half of 2024. Prominent healthcare investors participated in the financing, reflecting strong confidence in CalciMedica's progress. Additionally, the aggregate proceeds are expected to support subsequent clinical trials for both acute pancreatitis and AKI programs.
Read more →CALC▼ -13.9%on this news
CalciMedica Collaborator St. Jude Children
CalciMedica's collaborator, St. Jude Children's Research Hospital, has presented positive results from the Phase 1/2 CRSPA study of Auxora™ in treating asparaginase-induced pancreatic toxicity. The study showed that Auxora significantly reduced hospital stays and eliminated the need for nutritional support in pediatric patients with acute lymphoblastic leukemia. Additionally, there were no instances of significant pancreatic necrosis among treated patients, highlighting the potential benefits of Auxora in this challenging condition.
Read more →CALC▼ -12.7%on this news
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates Continued expansion of Phase 1/2 CRSPA study of Auxora in asparaginase-induced pancreatic toxicity (AIPT); data from init
CalciMedica provided updates on its clinical trials and financial results for Q3 2023. The company is expanding its Phase 1/2 CRSPA study of Auxora for asparaginase-induced pancreatic toxicity and anticipates Topline data from the Phase 2b CARPO trial in acute pancreatitis in early 2024. Despite a net loss of $4.6 million, CalciMedica's cash reserves are expected to sustain operations until Q3 2024.
Read more →CALC▲ +10.2%on this news· ran to +51% by day 3
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65 th Annual ASH Meeting & Exposition Auxora TM showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit
CalciMedica announced encouraging initial results from the CRSPA study of Auxora at the upcoming ASH Meeting. The data highlights improvements in pediatric patients with acute lymphoblastic leukemia experiencing asparaginase-associated pancreatitis. Patients treated with Auxora had significantly reduced hospital and ICU stays compared to a historical control group. The findings suggest potential therapeutic benefits for children affected by this condition.
Read more →CALCCalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompany
CalciMedica Inc. reported its financial results for the second quarter of 2023, highlighting significant advancements in clinical trials and corporate leadership changes. The company is expanding its Phase 2b CARPO trial for Auxora in acute pancreatitis to international locations, including India. An IND application for Auxora targeting acute kidney injury is expected by the end of 2023. Despite optimistic developments, the company faces uncertainties around regulatory approvals and market acceptance of its therapies.
Read more →CALC▲ +6.1%on this newsshared move
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica has announced the enrollment of the first patient in the international expansion of its CARPO trial, which evaluates Auxora™ for treating acute pancreatitis with systemic inflammatory response syndrome. The trial will include over 30 sites across the US and India, with top-line data expected in the first half of 2024. The study aims to demonstrate the efficacy and tolerability of Auxora in a life-threatening condition lacking approved therapies.
Read more →CALCBUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cel
CALC is advancing its lead product candidate Auxora, a CRAC channel inhibitor, which has demonstrated potential in treating various acute and chronic inflammatory conditions. Recent clinical trials indicate it significantly reduces recovery time and organ damage in acute pancreatitis and COVID-19 pneumonia patients. Upcoming Phase 2 trials aim to assess Auxora's efficacy in additional indications, including acute kidney injury and chronic pancreatitis, with topline results expected in 2024.
Read more →CALC▼ -7.9%on this news· ran to -37% by day 3
CalciMedica Developing First-in-Class Therapies for Acute Inflammatory Diseases with High Unmet Need June 2023 Forward-Looking Statements This presentation contains forward-looking statements which include, but are not l
CalciMedica is advancing the development of novel therapies targeting acute inflammatory diseases with significant unmet medical needs. The company's lead candidate, Auxora, has completed several clinical trials, demonstrating positive outcomes and a favorable safety profile. CalciMedica faces various risks, including regulatory approval challenges and market fluctuations, which could impact their business strategy and future success. Data from ongoing clinical trials is anticipated to be released in the first half of 2024, potentially influencing the company's trajectory.
Read more →CALCCalciMedica Announces Relisting on Nasdaq
CalciMedica Inc. has announced its relisting on the Nasdaq Capital Market, effective June 14, 2023, under the ticker symbol 'CALC'. This relisting aims to enhance trading liquidity and broaden investor access. The company continues to focus on its clinical trials for Auxora, a treatment for life-threatening inflammatory diseases.
Read more →CALC▲ +16.9%on this news
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
CalciMedica has announced the publication of preclinical findings in the Journal of Clinical Investigation, which highlight the potential of CRAC channel inhibitors, specifically Orai1 inhibitors, in preventing the progression of chronic pancreatitis. The study demonstrated that Orai1 inhibition reduced aberrant calcium signaling and tissue damage in mouse models of recurrent acute pancreatitis and early chronic pancreatitis. Encouragingly, CalciMedica is moving towards clinical studies for these compounds, with expectations for clinical applications beginning in late 2024. The findings suggest a novel treatment avenue for patients who currently have no specific therapies.
Read more →CALC▲ +9.5%on this news
CalciMedica Expands Executive Team with New Appointments
CalciMedica Inc. has announced the addition of Raven Jaeger as Chief Regulatory Officer and Andrew Cunningham as Senior Vice President of Clinical Development. Both leaders bring substantial industry experience, with Jaeger previously working at Diffusion Pharmaceuticals and Cunningham at various pharmaceutical companies, including Taysha Gene Therapies and Takeda. Their appointments reflect CalciMedica's commitment to advancing its clinical programs, particularly its lead product candidate, Auxora, which addresses unmet needs in the treatment of acute pancreatitis and other inflammatory diseases. This move marks a significant step for CalciMedica as it aims to grow in the biopharmaceutical space post-merger.
Read more →CALCCalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Inc. announced its financial results for the first quarter of 2023, highlighting a strong cash position that will last into the second half of 2024. The company is focusing on its lead compound, Auxora, which is in development for acute pancreatitis and other inflammatory conditions, with ongoing clinical trials showing promising results. However, it reported a net loss of $19.3 million during the quarter, and there remain no approved therapies for the conditions it aims to address.
Read more →CALCCalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
CalciMedica has successfully completed its merger with Graybug Vision, which will allow its stock to trade on Nasdaq under the ticker 'CALC' starting March 21, 2023. The merger provides CalciMedica with approximately $34 million in cash, supporting its operations and the advancement of its lead product candidate, Auxora, through clinical milestones in 2023. The company is focused on developing therapies for life-threatening inflammatory diseases, with key trial results expected in the near future.
Read more →CALCGraybug Announces Name and Trading Symbol Change
Graybug Vision, Inc. has officially changed its name to CalciMedica, Inc., effective March 20, 2023. This change coincides with the company's new trading symbol 'CALC' on the Nasdaq Global Market starting March 21, 2023. The name change is part of a merger with CalciMedica, aimed at enhancing its focus on therapies for inflammatory diseases.
Read more →CALCNOTE PURCHASE AGREEMENT T HIS N OTE P URCHASE A GREEMENT (this Agreement ) is made as of
CALCIMEDICA, INC. has entered into a Note Purchase Agreement with GRAYBUG VISION, INC. to secure a bridge loan of up to $2 million. This financial support aims to facilitate CALCIMEDICA's business operations and aid in the consummation of an existing merger. The agreement outlines specific terms for loan distribution, including an initial closing of $500,000 and procedures for subsequent closings. This strategic move reflects CALCIMEDICA's proactive approach to maintaining liquidity during a critical period.
Read more →CALCOPERATOR]: Ladies and gentlemen, thank you for standing by and welcome to the Graybug and CalciMedica Merger Announcement call. I would now like to turn the call over to Fred Guerard, Chief Executive Officer of Graybug.
[OPERATOR]: Ladies and gentlemen, thank you for standing by and welcome to the Graybug and CalciMedica Merger Announcement call. I would now like to turn the call over to Fred Guerard, Chief Executive [FRED GUERARD]: Thank you for joining us today. I m Fred Guerard, Chief Exec
Read more →CALCGraybug and CalciMedica Enter into Definitive Merger Agreement
Graybug Vision and CalciMedica have announced a definitive merger agreement to form a Nasdaq-listed biopharmaceutical company focused on developing CalciMedica's lead candidate, Auxora, for life-threatening inflammatory diseases. The merger is expected to close in Q1 2023, providing the combined entity with approximately $35 million in cash to fund clinical trials. The companies aim to advance Auxora through multiple clinical milestones in 2023.
Read more →CALCGraybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
Graybug Vision reported a net loss of $9.8 million for Q3 2022, up from $8.0 million in Q3 2021. The company has terminated its GB-102 and GB-401 programs, leading to restructuring costs of $2.4 million. Despite a decrease in research and development expenses, overall financial results indicate ongoing challenges, with a total net loss of $28.2 million for the nine months ended September 30, 2022.
Read more →CALCGraybug Vision, Inc. 203 Redwood Shores Parkway Suite 620 Redwood City, CA 94065 www.graybug.vision Graybug Vision Reports Financial Results for the Three and Nine Months Ended
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022 REDWOOD CITY, Calif., November 10, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY) ( Graybug or the Company ), a clinical-stage biopharmaceutical company focused historically on developi
Read more →CALCGraybug Vision Reports Financial Results for the Three and Six Months Ended
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments BALTIMORE, August 11, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicine
Read more →CALCGraybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments BALTIMORE
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments BALTIMORE, May 10, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provi
Read more →CALCGraybug Vision, Inc. 6411 Beckley Street Suite North 200 (N200) Baltimore, MD 21224 www.graybug.vision Graybug Vision Appoints Dirk Sauer to Board of Directors
Graybug Vision Appoints Dirk Sauer to Board of Directors BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announ
Read more →CALCGraybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments Management to host R&D Day for investors on
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET BALTIMORE, March 10, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused
Read more →CALCGraybug Vision, Inc. 6411 Beckley Street Suite North 200 (N200) Baltimore, MD 21224 www.graybug.vision Graybug Vision Announces Financial Results for the Three and Nine Months Ended
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments BALTIMORE, November 11, 2021 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformati
Read more →CALCGraybug Vision, Inc. 275 Shoreline Drive, Suite 450 Redwood City, CA 94065 www.graybug.vision Graybug Vision Announces Financial Results for the Three and Six Months Ended
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments REDWOOD CITY, Calif., August 11, 2021 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transform
Read more →CALCGraybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., May 12, 2021 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o
Read more →CALCCalciMedica Announces $21 Million Series D Financing
Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Zafi Avnur, Ph.D., chief scientific offi
Read more →CALCGraybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., March 4, 2021 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of d
Read more →CALCCalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”
Read more →CALCCalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
Blinded placebo-controlled trial is expected to enroll more than 100 patients at U.S. clinical sites by end of December The Company expects to complete enrollment of the trial by the end of Q1 2021 LA JOLLA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedi
Read more →CALCCalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of stroke CRAC channel inhibitors represent an important future potential therapeutic option for patients with ischemic stroke LA JOLLA, Calif., Nov. 13,
Read more →CALCGraybug Vision Announces Financial Results for the Three and Nine Months Ended
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments REDWOOD CITY, Calif., November 12, 2020 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing tra
Read more →CALCCalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium
Read more →CALCCalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia
Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S.
Read more →CALCCalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline LA JOLLA, Calif. and SZEGED, Hungary and BUDAPEST, Hungary, July 21,
Read more →CALCCalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to
Read more →CALCCalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone LA JOLLA, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechno
Read more →CALCCalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium rele
Read more →CALCCalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced tha
Read more →CALCCalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced tha
Read more →CALCCalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy
Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients LA JOLLA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated
Read more →CALCCalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for its CRAC Channel Inhibitor CM4620 at APA Annual Meeting
LA JOLLA, Calif., Nov. 7, 2019 /PRNewswire/ -- Kenneth Stauderman, Ph.D., CalciMedica's Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual meeting November 7-10 in Wailea, Hawaii, entitled "Pharmacodynamic (PD)/Pharmacokinetic (PK) Study
Read more →CALCHenry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica
LA JOLLA, Calif., Oct. 30, 2019 /PRNewswire/ -- Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a key Principal Investigator on CalciMedica's initial acute pancreatitis clinical study of its calcium release-activated calcium (CRAC) channel i
Read more →CALCCalciMedica Names Life Science Veteran to its Board of Directors
LA JOLLA, Calif., March 26, 2019 /PRNewswire/ -- CalciMedica, a clinical-stage biopharmaceutical company developing CM4620, a novel small molecule compound for acute pancreatitis, announced that A. Rachel Leheny, Ph.D., has joined its Board of Directors. Dr. Leheny is a Founding
Read more →CALCCalciMedica, Inc. to Present Study Population Profile from its Initial Patient Study of its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference
LA JOLLA, Calif., March 19, 2019 /PRNewswire/ -- Physicians from several study sites involved in CalciMedica's initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 (NCT03401109) and CalciMedica, Inc., presented a poster today at the 39th International Sy
Read more →CALCCalciMedica Doses First Patients in Acute Pancreatitis Clinical Study
LA JOLLA, Calif., Aug. 1, 2018 /PRNewswire/ -- CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620. The study is intended to provid
Read more →CALCCalciMedica Names Two Senior Executives to its Board of Directors
LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-foun
Read more →CALCResearch Collaboration between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference
LA JOLLA, Calif., Jan. 24, 2018 /PRNewswire/ -- Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the International Stroke Conference being held in Los Angeles that describes the use of one of CalciMedic
Read more →CALCCalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis
LA JOLLA, Calif., May 24, 2017 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced today that it received Fast-Track designation from the U.S. Food and Drug Administration (US FDA) for its lead clinical compound, CM4620, a novel, calcium release-activated calcium (CRAC) c
Read more →CALCCalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
LA JOLLA, Calif., Jan. 6, 2017 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis. Acute panc
Read more →CALCSan Francisco VA, UCSF and CalciMedica, Inc. Present Results on CRAC Channel Inhibitors in Traumatic Brain Injury Model at Neuroscience Meeting
LA JOLLA, Calif., Nov. 15, 2016 /PRNewswire/ -- Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the 46th annual Society for Neuroscience meeting in San Diego describing the use of calcium release-activ
Read more →CALCCalciMedica Announces Senior Clinical Development Hire
LA JOLLA, Calif., Nov. 14, 2016 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced that Sudarshan Hebbar, MD, has joined the company as Senior Vice President, Clinical Development, to lead its clinical efforts for the development of novel calcium release-activated calciu
Read more →CALCCalciMedica, Inc. and the University of Liverpool Announce Publication on CRAC Channel Inhibitors for Acute Pancreatitis
LA JOLLA, Calif., July 24, 2015 /PRNewswire/ -- Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancr
Read more →Competitive Position
How CALC ranks across every disease it competes inCompetitive Position is a premium feature
See how CALC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial